• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BLT
Click for more information
5.77% 5.5¢

BENITEC BIOPHARMA LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BLT INVESTOR PRESENTATION05/08/14
BLT Appendix 3B04/08/14
BLT Appendix 4C - quarterlyPRICE SENSITIVE30/07/14
BLT s708 Cleansing Statement30/07/14
BLT Change of Director's Interest Notice30/07/14
BLT Change of Director's Interest Notice30/07/14
BLT Appendix 3B30/07/14
BLT HCV TRIAL UPDATEPRICE SENSITIVE21/07/14
BLT BIOSHARES CLINICAL TRIALS PRESENTATION18/07/14
BLT ATTACHMENT TO GUIDANCE ON TRIALS ANNOUNCEMENT11/07/14
BLT GUIDANCE ON CLINICAL TRIAL UPDATESPRICE SENSITIVE11/07/14
BLT UNMARKEATBLE PARCELS01/07/14
BLT CALIMMUNE TRIAL ADVANCESPRICE SENSITIVE26/06/14
BLT Change in substantial holding24/06/14
BLT Final Director's Interest Notice20/06/14
BLT DIRECTOR RESIGNATION19/06/14
BLT NON DEAL ROADSHOW PRESENTATION11/06/14
BLTFEDERAL R&D GRANT RECEIVEDPRICE SENSITIVE06/06/14
BLTUS ADR PROGRAM LAUNCHED02/06/14
BLTUS ADR TO BE ESTABLISHED30/05/14
BLTHEPATITIS C PATIENT DOSING COMMENCEDPRICE SENSITIVE29/05/14
BLTEUROPEAN PATENTS UPDATEPRICE SENSITIVE23/05/14
BLTCEO PRESENTATION AT BIOTECH BRUSSELS20/05/14
BLTUPDATE ON HEPATITIS C TRIAL12/05/14
BLTASTRA-ZENECA PRESENTATION30/04/14
BLTAppendix 4C - quarterlyPRICE SENSITIVE30/04/14
BLTChange in substantial holding17/04/14
BLTAppendix 3B15/04/14
BLTAUD 31.5 MILLION PLACEMENT COMPLETEDPRICE SENSITIVE15/04/14
BLTCleansing Notice15/04/14
BLTAppendix 3B15/04/14
BLTCleansing notice15/04/14
BLTAppendix 3B15/04/14
BLTResults of Meeting10/04/14
BLTGENERAL MEETING PRESENTATION10/04/14
BLTChairman's Address to Shareholders10/04/14
BLTPRESENTATION - BIOMELBOURNE08/04/14
BLTPRESENTATION AT BIOMELBOURNE08/04/14
BLTChange of Director's Interest Notice20/03/14
BLTAppendix 3B20/03/14
BLTCraig Lewis appointed Chief Medical Adviser17/03/14
BLTINVESTOR PRESENTATION14/03/14
BLTLISTED OPTIONS EXPIRY NOTICE13/03/14
BLTHCV PATIENT DOSING TIMINGPRICE SENSITIVE13/03/14
BLTBecoming a substantial holder12/03/14
BLTNotice of General Meeting/Proxy Form11/03/14
BLTCeasing to be a substantial holder11/03/14
BLTAppendix 3B07/03/14
BLTChange of Director's Interest Notice07/03/14
BLTChange in substantial holding07/03/14
BLTCeasing to be a substantial holder06/03/14
BLTCeasing to be a substantial holder06/03/14
BLTs708 Cleansing Statement28/02/14
BLTAppendix 3B28/02/14
BLTFIRST STAGE OF PLACEMENT RAISES AUD15.7 MILLIONPRICE SENSITIVE28/02/14
BLTHalf Yearly Report and AccountsPRICE SENSITIVE27/02/14
BLTDR PETER FRENCH DISCUSSES A$31.5 MILLION PLACEMENT26/02/14
BLTBENITEC RAISES UP TO AUD31.5 MILLIONPRICE SENSITIVE24/02/14
BLTResponse to ASX queryPRICE SENSITIVE21/02/14
BLTUNIVERSITY OF WESTMINSTER ROLE IN TT-034PRICE SENSITIVE18/02/14
BLTAppendix 3B07/02/14
BLTNATURE PUBLICATION07/02/14
BLTAppendix 4C - quarterlyPRICE SENSITIVE31/01/14
BLTAppendix 3B Correction29/01/14
BLTAppendix 3B28/01/14
BLTAppendix 3B14/01/14
BLTHEPATITIS C TRIAL TO PROCEEDPRICE SENSITIVE14/01/14
BLTBIOTECH SHOWCASE PRESENTATION13/01/14
BLTIND UpdatePRICE SENSITIVE06/01/14
BLTAppendix 3B06/01/14
BLTUNSW COLLABORATOR ON HIGH ACHIEVERS LIST24/12/13
BLTOPTION EXPIRY CORRECTION20/12/13
BLTOPTIONS EXPIRY19/12/13
BLTPOSITIVE LUNG CANCER PRECLINICAL RESULTSPRICE SENSITIVE18/12/13
BLTNEW TT-034 PAPER ACCEPTED FOR PUBLICATION10/12/13
BLTIND APPLICATION FOR TT-034 SUBMITTEDPRICE SENSITIVE09/12/13
BLTChange of Director's Interest Notice18/11/13
BLTAppendix 3B18/11/13
BLTAGM VOTING RESULTS14/11/13
BLTAGM CHAIRMANS ADDRESS14/11/13
BLTAGM PRESENTATION14/11/13
BLTAppendix 4C - quarterlyPRICE SENSITIVE31/10/13
BLTs708 Cleansing Statement30/10/13
BLTAppendix 3B30/10/13
BLTTACERE ESCROW RELEASE23/10/13
BLTAppendix 3B22/10/13
BLTResponse to ASX Price queryPRICE SENSITIVE17/10/13
BLTAnnual Report to shareholders15/10/13
BLTNotice of Annual General Meeting/Proxy Form15/10/13
BLTINVESTOR PRESENTATION WEBCAST27/09/13
BLTCANCER PROGRAM WINS INNOVATION AWARD13/09/13
BLTCORPORATE PRESENTATION12/09/13
BLTPreliminary Final ReportPRICE SENSITIVE30/08/13
BLTAppendix 3B27/08/13
BLTInitial Director's Interest Notice26/08/13
BLTDR PETER FRENCH APPOINTED TO BOARDPRICE SENSITIVE26/08/13
BLTHEPATITIS C PRESENTATION HCV 201315/08/13
BLTBENITEC OBTAINS LICENCE FROM UNIVERSITY OF NSWPRICE SENSITIVE08/08/13
BLTAppendix 3B06/08/13
BLTREGEN LICENCE FOR CANCER VACCINESPRICE SENSITIVE06/08/13
BLT INVESTOR PRESENTATION
05/08/14
BLT Appendix 3B
04/08/14
BLT Appendix 4C - quarterly
30/07/14PRICE SENSITIVE
BLT s708 Cleansing Statement
30/07/14
BLT Change of Director's Interest Notice
30/07/14
BLT Change of Director's Interest Notice
30/07/14
BLT Appendix 3B
30/07/14
BLT HCV TRIAL UPDATE
21/07/14PRICE SENSITIVE
BLT BIOSHARES CLINICAL TRIALS PRESENTATION
18/07/14
BLT ATTACHMENT TO GUIDANCE ON TRIALS ANNOUNCEMENT
11/07/14
BLT GUIDANCE ON CLINICAL TRIAL UPDATES
11/07/14PRICE SENSITIVE
BLT UNMARKEATBLE PARCELS
01/07/14
BLT CALIMMUNE TRIAL ADVANCES
26/06/14PRICE SENSITIVE
BLT Change in substantial holding
24/06/14
BLT Final Director's Interest Notice
20/06/14
BLT DIRECTOR RESIGNATION
19/06/14
BLT NON DEAL ROADSHOW PRESENTATION
11/06/14
BLTFEDERAL R&D GRANT RECEIVED
06/06/14PRICE SENSITIVE
BLTUS ADR PROGRAM LAUNCHED
02/06/14
BLTUS ADR TO BE ESTABLISHED
30/05/14
BLTHEPATITIS C PATIENT DOSING COMMENCED
29/05/14PRICE SENSITIVE
BLTEUROPEAN PATENTS UPDATE
23/05/14PRICE SENSITIVE
BLTCEO PRESENTATION AT BIOTECH BRUSSELS
20/05/14
BLTUPDATE ON HEPATITIS C TRIAL
12/05/14
BLTASTRA-ZENECA PRESENTATION
30/04/14
BLTAppendix 4C - quarterly
30/04/14PRICE SENSITIVE
BLTChange in substantial holding
17/04/14
BLTAppendix 3B
15/04/14
BLTAUD 31.5 MILLION PLACEMENT COMPLETED
15/04/14PRICE SENSITIVE
BLTCleansing Notice
15/04/14
BLTAppendix 3B
15/04/14
BLTCleansing notice
15/04/14
BLTAppendix 3B
15/04/14
BLTResults of Meeting
10/04/14
BLTGENERAL MEETING PRESENTATION
10/04/14
BLTChairman's Address to Shareholders
10/04/14
BLTPRESENTATION - BIOMELBOURNE
08/04/14
BLTPRESENTATION AT BIOMELBOURNE
08/04/14
BLTChange of Director's Interest Notice
20/03/14
BLTAppendix 3B
20/03/14
BLTCraig Lewis appointed Chief Medical Adviser
17/03/14
BLTINVESTOR PRESENTATION
14/03/14
BLTLISTED OPTIONS EXPIRY NOTICE
13/03/14
BLTHCV PATIENT DOSING TIMING
13/03/14PRICE SENSITIVE
BLTBecoming a substantial holder
12/03/14
BLTNotice of General Meeting/Proxy Form
11/03/14
BLTCeasing to be a substantial holder
11/03/14
BLTAppendix 3B
07/03/14
BLTChange of Director's Interest Notice
07/03/14
BLTChange in substantial holding
07/03/14
BLTCeasing to be a substantial holder
06/03/14
BLTCeasing to be a substantial holder
06/03/14
BLTs708 Cleansing Statement
28/02/14
BLTAppendix 3B
28/02/14
BLTFIRST STAGE OF PLACEMENT RAISES AUD15.7 MILLION
28/02/14PRICE SENSITIVE
BLTHalf Yearly Report and Accounts
27/02/14PRICE SENSITIVE
BLTDR PETER FRENCH DISCUSSES A$31.5 MILLION PLACEMENT
26/02/14
BLTBENITEC RAISES UP TO AUD31.5 MILLION
24/02/14PRICE SENSITIVE
BLTResponse to ASX query
21/02/14PRICE SENSITIVE
BLTUNIVERSITY OF WESTMINSTER ROLE IN TT-034
18/02/14PRICE SENSITIVE
BLTAppendix 3B
07/02/14
BLTNATURE PUBLICATION
07/02/14
BLTAppendix 4C - quarterly
31/01/14PRICE SENSITIVE
BLTAppendix 3B Correction
29/01/14
BLTAppendix 3B
28/01/14
BLTAppendix 3B
14/01/14
BLTHEPATITIS C TRIAL TO PROCEED
14/01/14PRICE SENSITIVE
BLTBIOTECH SHOWCASE PRESENTATION
13/01/14
BLTIND Update
06/01/14PRICE SENSITIVE
BLTAppendix 3B
06/01/14
BLTUNSW COLLABORATOR ON HIGH ACHIEVERS LIST
24/12/13
BLTOPTION EXPIRY CORRECTION
20/12/13
BLTOPTIONS EXPIRY
19/12/13
BLTPOSITIVE LUNG CANCER PRECLINICAL RESULTS
18/12/13PRICE SENSITIVE
BLTNEW TT-034 PAPER ACCEPTED FOR PUBLICATION
10/12/13
BLTIND APPLICATION FOR TT-034 SUBMITTED
09/12/13PRICE SENSITIVE
BLTChange of Director's Interest Notice
18/11/13
BLTAppendix 3B
18/11/13
BLTAGM VOTING RESULTS
14/11/13
BLTAGM CHAIRMANS ADDRESS
14/11/13
BLTAGM PRESENTATION
14/11/13
BLTAppendix 4C - quarterly
31/10/13PRICE SENSITIVE
BLTs708 Cleansing Statement
30/10/13
BLTAppendix 3B
30/10/13
BLTTACERE ESCROW RELEASE
23/10/13
BLTAppendix 3B
22/10/13
BLTResponse to ASX Price query
17/10/13PRICE SENSITIVE
BLTAnnual Report to shareholders
15/10/13
BLTNotice of Annual General Meeting/Proxy Form
15/10/13
BLTINVESTOR PRESENTATION WEBCAST
27/09/13
BLTCANCER PROGRAM WINS INNOVATION AWARD
13/09/13
BLTCORPORATE PRESENTATION
12/09/13
BLTPreliminary Final Report
30/08/13PRICE SENSITIVE
BLTAppendix 3B
27/08/13
BLTInitial Director's Interest Notice
26/08/13
BLTDR PETER FRENCH APPOINTED TO BOARD
26/08/13PRICE SENSITIVE
BLTHEPATITIS C PRESENTATION HCV 2013
15/08/13
BLTBENITEC OBTAINS LICENCE FROM UNIVERSITY OF NSW
08/08/13PRICE SENSITIVE
BLTAppendix 3B
06/08/13
BLTREGEN LICENCE FOR CANCER VACCINES
06/08/13PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor The ASX200 has been really flirting with the 8,500pts mark this week, notching an intraweek ATH of 8,476pts.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.